Progression of HIV to AIDS: A protective role for HLA-B27?

AIDS Reviews

Volumn 6, Issue 2, 2004, Pages 89-96

  den Uyl, Debby ^a   van der Horst Bruinsma, Irene E ^a,b   van Agtmael, Michiel ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

AIDS; Disease progression; HIV; HLA B27; Spondyloarthropathy

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; EPITOPE; GAG PROTEIN; HLA A24 ANTIGEN; HLA ANTIGEN; HLA B27 ANTIGEN; HLA B35 ANTIGEN; HLA DR1 ANTIGEN; HLA DR3 ANTIGEN; HLA DR6 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN; RANTES; STROMAL CELL DERIVED FACTOR 1; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLELE; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIGEN PRESENTATION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HETEROZYGOTE; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENETICS; INFECTION CONTROL; NONHUMAN; PROGNOSIS; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ALLELES; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HLA-B27 ANTIGEN; HUMANS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 4344577957     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Ogg G, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279:2103-6.
2. McMichael A, Rowland-Jones S. Cellular immune responses to HIV. Nature 2001;410:980-7.
3. McMichael A. T-cell responses and viral escape. Cell 1998;93:673-6.
4. Kaslow R, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996;2:405-11.
5. McNeil A, Yap P, Gore S, et al. Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. Q J Med 1996;89:177-85.
6. Magierowska M, Theodorou I, Debré P, et al,Combined genotypes of CCR5, CCR2, SDF1 and HLA genes can predict the long-term non-progressor status in HIV-1-Infected individuals. Blood 1999; 93:936-41.
7. Gore S, Hutchinson S, Brettle R. Study requirements for investigating HLA-associated progression of HIV-disease, and review. Q J Med 1999;92:609-17.
8. Buchbinder S, Katz M, Hessol N, O'Malley P, Holmberg S. Long-term HIV-1 infection without immunological progression. AIDS 1994;8:1123-82.
9. Easterbrook P. Long-term non-progression in HIV infection: definitions and epidemiological issues. J Infect 1999;38:71-3.
10. Keet I, Tang J, Klein M, et al. Consistent associations of HLA Class I and II and transporter gene products with progression of HIV-1 infection in homosexual men. J Infect Dis 1999; 180:299-309.
11. Hendel H, Caillat-Zucman S, Lebuanec H, et al. New Class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol 1999;162:6942-6.
12. McMichael A, Bowness P. HLA-B27: natural function and pathogenic role in spondylarthritis. Arthritis Res 2002;4(Suppl 3):153-8.
13. Khan M. Epidemiology of HLA-B27 and arthritis. Clin Rheumatol 1996;15(Suppl 1):0-2.
14. Khare S, Luthra H, David C. HLA-B27 and other predisposing factors in spondyloarthropathies. Curr Opin Rheumatol 1998;10:282-91.
15. Boyle L, Hill-Gaston J. Breaking the rules: the unconventional recognition of HLA-B27 by CD4+ T lymphocytes as an insight into the pathogenesis of the spondyloarthropathies. Rheumatol 2003;42:404-12.
16. Kvien T, Glennas A, Melby K, et al. Reactive arthritis: incidence, triggering agents and clinical presentation. J Rheumatol 1994; 21:115-22.
17. Taurog J, Maika A, Satumtira N, et al. Inflammatory disease in HLA-B27 transgenic rats. Immunol Rev 1999;169:209-23.
18. Lahesmaa R, Skurnik M, Vaara M, Leirisalo-Repo M, Nissila M, Granfors K. Molecular mimicry between HLA-B27 and Yersinia, Salmonella, Shigella and Klebsiella within the same region of HLA alpha 1-helix. Clin Exp Immunol 1991;86:399-404.
19. Benjamin R, Madrigal J, Parham P. Peptide binding to empty HLA-B27 molecules of viable human cells. Nature 1991;351:74-7.
20. Khare S, Bull M, Hanson J, Luthra H, David C. Spontaneous inflammatory disease in HLA-B27 transgenic mice is independent of MHC class II molecules: a direct role for B27 heavy chains and not B27-derived peptides. J Immunol 1998;160:101-6.
21. Khan M. Update: the twenty subtypes of HLA-B27. Curr Opin Rheumatol 2000;12:235-8.
22. Parham P, Ohta T, Population biology of antigen presentation by MHC Class I molecules, Science 1996;272:67-74.
23. Brown R Jr, Gaglio P. Scope of Worldwide Hepatitis C problem. Liver Transpl 2003;9(Suppl):10-3.
24. WHO. Communicable Disease Surveillance & Response (Available from URL: www.who.int/csr/disease/en/).
25. Voeten J, Bestebroer T, Nieuwkoop N, Fouchier R, Osterhaus A, Rimmelzwaan G. Antigenic drift in the influenza A virus (H3N2) nucleoprotein and espace from recognition by cytotoxic T lymphocytes, J Virol, 2000 Aug;74(15):6800-7.
26. Brooks J, Colbert R, Mear J, Leese A, Rickinson A, HLA-B27 subtype polymorphism and CTL epitope choice: studies with EBV peptides link immunogenicity with stability of the B27-peptide complex. J Immunol 1998;161:5252-9.
27. Lekstrom-Himes J, Hohman P, Warren T. Association of major histocompatibility complex determinants with the development of symptomatic and asymptomatic genital herpes simplex virus type 2 infections. J Infect Dis 1999;179:1077-85.
28. Mustonen J, Partanen J, Kanerva M, Pietila K, Vapalhti O. Association of HLA-B27 with benign clinical course of nephropathia epidemica caused by Puumala Hantavirus. Scand J Immunol 1998;47:277-9.
29. Borrow P, Lewicki H, Wei X, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med 1997;3:205-11.
30. Trachtenberg E, Korber B, Sollars C, et al. Advantage of rare HLA super-type in HIV disease progression. Nat Med 2003;9:928-35.
31. Kelleher A, Long C, Holmes E, et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 2001; 193:375-85.
32. Nowak M, May R, Philips R, et al. Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 1995;375:606-11.
33. Nelson G, Kaslow R, Mann D, Frequency of HLA allele-specific peptide motifs in HIV-1 proteins correlates with the allele's association with relative rates of disease progression after HIV-1 infection. Proc Natl Acad Sci USA 1997;94:9802-7.
34. Douglas L, Mayers M. Drug-resistant HIV-1. JAMA 1998;279:2000-2.
35. Pantaleo G, Demarest J, Schacker T, et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci USA 1997;94:254-8,
36. Rosenberg E, Billingsley J, Angela M, et al. Vigorous HIV-1-specific CD4+ T-cell responses associated with control of viremia. Science 1997;278:1447-50.
37. Carrington M, Nelson G, Martin M, et al. HLA and HIV-1: heterozygotic advantage and B*35-Cw*04 disadvantage. Science 1999; 283:1748-52.
38. Smith P, Sarner L, Murphy M, et al. Ethnicity and discordance in plasma HIV-1 RNA viral load and CD4+ lymphocyte count in a cohort of HIV-1-infected individuals. J Clin Virol 2003;26:101-7.
39. Flores-Villanueva P, Yunis J, Delgado J, et al. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc Natl Acad Sci USA 2001;98:5140-5.
40. Huber C, Pons O, Hendel H, et al. Genomic studies in AIDS: problems and answers. Development of a statistical model integrating both longitudinal cohort studies and transversal observations of extreme cases. Biomed Pharm 2003;57:28-33.
41. Nixon D, Townsend A, Elvin J, Rizza C, Gallwey J, McMichael A. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature 1988;336:484-7.
42. Goulder P, Phillips R, Colbert R, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997;3:212-7.
43. Nietfeld W, Bauer M, Revrier M, et al. Sequence constraints and recognition by CTL of an HLA-B27-restricted HIV-1 gag epitope. J Immunol 1995;154:2189-97.
44. Madden D, Gorga J, Strominger J, Wiley D. The three-dimensional structure of HLA-1327 at 2.1 Å resolution suggests a general mechanism for tight binding to MHC. Cell 1992; 70:1035-48,
45. Goulder P, Brander C, Tang Y, at al. Evolution and transmission of stable CTL escape mutations in HIV infection, Nature 2001;412:334-7.
46. McMichael A, Klenerman P. HLA leaves its footprints on HIV. Science 2002;296:1410-1.
47. Carrington M, Nelson G, O'Brien S. Considering genetic profiles in functional studies of immune responsiveness to HIV-1. Immunol Letters 2001;79:131-40.
48. Ioannidis J, Rosenberg P, Goedert J, et al. Effects of CCR5-Δ32, CCR2-641, and SDF-1 3′A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med 2001;135:782-95.